We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

109 hedge funds and large institutions have $682M invested in Vanda Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 44 increasing their positions, 26 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

139% more call options, than puts

Call options by funds: $32.6M | Put options by funds: $13.6M

79% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 14

69% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 26

59% more capital invested

Capital invested by funds: $428M → $682M (+$254M)

8% more funds holding

Funds holding: 101 → 109 (+8)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
109
Holders Change
+8
Holders Change %
+7.92%
% of All Funds
2.91%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
25
Increased
44
Reduced
26
Closed
14
Calls
$32.6M
Puts
$13.6M
Net Calls
+$19M
Net Calls Change
+$22.1M

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$23.3M
2
Morgan Stanley
Morgan Stanley
New York
+$8.62M
3
KCM
Kingdon Capital Management
New York
+$7.76M
4
PAI
Palo Alto Investors
California
+$5.96M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.63M

Top Sellers

Rank Fund Capital Flow
1
SCA
Signpost Capital Advisors
New York
-$8.82M
2
JGC
J. Goldman & Co
New York
-$8.23M
3
Goldman Sachs
Goldman Sachs
New York
-$6.51M
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$5.2M
5
JG
Jefferies Group
New York
-$2.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
Alyeska Investment Group
26
Alyeska Investment Group
Illinois
$4.01M +$1.28M +107,839 +63%
JGC
27
J. Goldman & Co
New York
$3.97M -$8.23M -695,327 -71%
Deutsche Bank
28
Deutsche Bank
Germany
$3.67M +$860K +72,714 +40%
Barclays
29
Barclays
United Kingdom
$3.31M +$2.77M +234,002 +10,884%
FLAM
30
First Light Asset Management
Minnesota
$3.29M +$2.72M +229,818 New
Geode Capital Management
31
Geode Capital Management
Massachusetts
$3.17M +$324K +27,365 +14%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$3.06M -$5.2M -439,653 -67%
Credit Agricole
33
Credit Agricole
France
$2.96M – – –
Principal Financial Group
34
Principal Financial Group
Iowa
$2.7M -$101K -8,513 -4%
Goldman Sachs
35
Goldman Sachs
New York
$2.56M -$6.51M -550,305 -75%
FM
36
Forward Management
California
$2.2M +$2.04M +172,300 New
TD Asset Management
37
TD Asset Management
Ontario, Canada
$2M +$241K +20,400 +17%
Ameriprise
38
Ameriprise
Minnesota
$1.92M +$870K +73,549 +121%
Macquarie Group
39
Macquarie Group
Australia
$1.86M – – –
BIM
40
BlackRock Investment Management
Delaware
$1.62M +$164K +13,875 +14%
QI
41
QS Investors
New York
$1.58M +$1.31M +110,486 New
Wellington Management Group
42
Wellington Management Group
Massachusetts
$1.42M -$119K -10,090 -9%
GGHC
43
Gilder Gagnon Howe & Co
New York
$1.21M +$16.8K +1,423 +2%
Citadel Advisors
44
Citadel Advisors
Florida
$1.17M +$948K +80,137 +5,204%
BCM
45
Bridgeway Capital Management
Texas
$1.15M – – –
CS
46
Credit Suisse
Switzerland
$1.13M +$563K +47,570 +151%
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$1.06M +$133K +11,267 +18%
JAM
48
JW Asset Management
Florida
$971K +$802K +67,746 New
GS
49
Gagnon Securities
New York
$950K -$97.6K -8,245 -11%
California Public Employees Retirement System
50
California Public Employees Retirement System
California
$879K – – –
1
2
3 4 5

VNDA Hedge Fund Activity: Q4 2014 in Review

109 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2014, worth a combined $682M — up 59% from $428M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new VNDA positions and 14 closed out — a net gain of 11 holders — while 44 added to existing stakes and 26 trimmed.

The largest buyer was Deerfield Management, adding an estimated $23.3M. The largest seller was Signpost Capital Advisors, cutting an estimated $8.82M.

  • 109 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2014, up from 101 in Q3 2014.
  • Funds reported $682M of Vanda Pharmaceuticals stock for Q4 2014, up 59% quarter-over-quarter.
  • 25 funds opened new Vanda Pharmaceuticals positions in Q4 2014 and 14 closed out, a net change of +11 holders.
  • The largest Vanda Pharmaceuticals buyer in Q4 2014 was Deerfield Management, an estimated $23.3M added.
  • The largest Vanda Pharmaceuticals seller in Q4 2014 was Signpost Capital Advisors, an estimated $8.82M sold.

Based on aggregated 13F filings for Q4 2014.